Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is making significant strides in its proposed merger with Scipher Medicine Corporation. The company has announced that the SEC has declared effective its Form S-4 registration statement, a crucial step towards finalizing the merger. A special meeting for Chemomab shareholders is scheduled for December 4, 2026, to vote on the merger, which is expected to close in the first quarter of 2027, pending approval.

This merger is particularly important as it aims to create a precision medicine powerhouse in immunology. Chemomab, a clinical-stage biotechnology firm, is focused on developing innovative therapeutics for immune-fibrotic diseases, which are often underserved in the pharmaceutical market.

Background

Chemomab Therapeutics Ltd. operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker CMMB. Its recent filings include a 6-K form submitted on November 19, 2026, detailing its financial results and corporate updates. The firm has undergone several name changes, previously known as Anchiano Therapeutics Ltd. and BioCancell Ltd.

What the Filing Says

The recent filing includes a press release stating, "Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update." It highlights the progress made towards the merger with Scipher, noting that the SEC's declaration of effectiveness of the Form S-4 registration statement is a significant milestone.

Impact

The proposed merger will directly affect Chemomab's shareholders, who will have the opportunity to vote on the merger at the upcoming special meeting. If approved, the merger will create a larger entity that combines Chemomab's clinical-stage anti-CCL24 antibody nebokitug with Scipher's precision medicine capabilities. This merger is anticipated to enhance the combined company's ability to address the substantial market for rheumatoid arthritis treatments, estimated at around $24 billion annually.

What's Next

The next step involves the special shareholder meeting on December 4, 2026, where Chemomab's shareholders will vote on the proposed merger with Scipher. If approved, the merger is expected to close in early 2027, contingent upon satisfying customary closing conditions.